Antabio
Labège
About Antabio
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. The company's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections. Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $73.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2023)
- Website: antabio.com
- Phone: +33 5 61 53 88 43
Industries & Categories
Biotechnology, Life Science, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/antabio-6001 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.